Denne siden ble automatisk oversatt og nøyaktigheten av oversettelsen er ikke garantert. Vennligst referer til engelsk versjon for en kildetekst.

CD19-rettet kimær antigenreseptor autologe T-celler (CART19) for lupus

21. september 2026 oppdatert av: Children's Hospital of Philadelphia

CD19-rettede kimære antigenreseptor autologe T-celler (CART19) for ungdommer og unge voksne med systemisk lupus erythematosis (SLE)

This is a single-center, single-arm, open-label phase 1/2 study of CART19 in children and young adults with refractory Systemic lupus erythematosus (SLE), including both patients diagnosed with lupus nephritis (LN) and patients with non-renal Systemic lupus erythematosus (SLE).

Phase 1 will evaluate the safety of CART19 in 6-12 patients with Systemic lupus erythematosus (SLE). There is no planned dose escalation, but a dose de-escalation will be made based on the incidence of Dose Limiting Toxicities. Phase 2 will evaluate the efficacy and further evaluate the safety of CART19 in this population.

Studieoversikt

Detaljert beskrivelse

Lupus disease activity is associated with increased numbers of activated naïve B cells and polyclonal expansion of antibody secreting cells, indicating a central role for B cells in the pathogenesis of SLE. While traditional anti-CD19 antibody therapies have been utilized with varying success in the treatment of Systemic lupus erythematosus (SLE), CD19 directed cellular therapies have emerged as an attractive therapeutic option that may lead to immunosuppression-free remission in this population given the ability of CD19 directed CAR T cells to more deeply deplete the B cell compartment. Previous clinical experience utilizing CD19 directed CAR T cells in patients diagnosed with Systemic lupus erythematosus (SLE) have exceeded any other Systemic lupus erythematosus (SLE) therapeutic available; although, those clinical trials have treated a limited number of subjects. During this trial the test article will be CART19 cells transduced with a lentiviral vector to express anti-CD19 scFv:41-BB:TCRζ, administered by IV injection.

Studietype

Intervensjonell

Registrering (Antatt)

24

Fase

  • Fase 2
  • Fase 1

Kontakter og plasseringer

Denne delen inneholder kontaktinformasjon for de som utfører studien, og informasjon om hvor denne studien blir utført.

Studiekontakt

Studer Kontakt Backup

Studiesteder

    • Pennsylvania
      • Philadelphia, Pennsylvania, Forente stater, 19104
        • Rekruttering
        • Children's Hospital of Philadelphia
        • Ta kontakt med:
        • Hovedetterforsker:
          • Caitlin Elgarten, MD
        • Ta kontakt med:

Deltakelseskriterier

Forskere ser etter personer som passer til en bestemt beskrivelse, kalt kvalifikasjonskriterier. Noen eksempler på disse kriteriene er en persons generelle helsetilstand eller tidligere behandlinger.

Kvalifikasjonskriterier

Alder som er kvalifisert for studier

10 år til 29 år (Barn, Voksen)

Tar imot friske frivillige

Nei

Kjønn som er kvalifisert for studier

Alle

Beskrivelse

Inclusion Criteria:

  1. Signed informed consent form must be obtained prior to any study procedure. Labs or other procedures obtained during routine clinical care may be used for eligibility if obtained within the protocol required window.

  2. Patient age must be 10-29 years, inclusive, at time of enrollment.

  3. Meeting ACR/EULAR Classification Criteria for SLE

  4. ANA positive > 1:80 and/or double-stranded DNA (dsDNA) positive

  5. Active (refractory) disease, defined as follows:

    a. Lupus nephritis subjects must meet both the following criteria: i. ISN/RPS active nephritis Class III/IV +/- V lupus nephritis diagnosed by biopsy within past 12 months.

ii. Persistent and clinically significant: ≥2 measurements with urine protein with either of the following:

  1. > 1mg/mg creatinine
  2. > 0.5 mg/mg creatinine associated with renal dysfunction or low albumin.
  3. > 0.5 mg/mg creatinine in a patient with rising proteinuria after prior complete renal response b. Non-renal SLE subjects must meet either of the following criteria: i. SLEDAI-2K ≥ 8 and clinical SLEDAI-2K ≥ 6 ii. Inability to decrease prednisone ≤7.5mg/day or 0.15mg/kg/day, whichever is lower, due to active disease.

6. Patients must have had at least 3 months of cumulative conventional therapy defined as:

  1. Conventional induction immunosuppressive agent(s) (e.g., mycophenolate mofetil, cyclophosphamide), and
  2. At least one additional therapy:

i. B-cell directed biologic therapy (e.g., rituximab, belimumab, ofatumumab, obinutuzumab) ii. Calcineurin inhibitor (e.g., tacrolimus, cyclosporine, voclosporin) iii. Other immunosuppressive medication for SLE (e.g., anifrolumab, abatacept, JAK inhibitor) 7. Adequate organ function status

  1. Renal: eGFR must be ≥30 and subject cannot be receiving dialysis.

  2. Hepatic: Transaminases < 5x upper limit of normal and serum conjugated (Direct) bilirubin <1.5x upper limit of normal unless attributable to SLE. If attributable to autoimmune disease, Child-Pugh score must be class A or class B. Child-Pugh score cannot be class C.

  3. Cardiac: Shortening fraction > 28%, left ventricular ejection fraction >45%, and no evidence of severe pulmonary hypertension

  4. Pulmonary: Must have a minimum level of pulmonary reserve defined as ≤ Grade 1 dyspnea and <Grade 3 hypoxia; DLCO ≥40% (corrected for anemia and/or VA volume if necessary) if PFTs are clinically appropriate as determined by the treating investigator.

    8. Subjects of reproductive potential must agree to use acceptable birth control methods.

Exclusion Criteria:

  1. Active, untreated infections

  2. HIV infection

  3. Active Hepatitis B

    a. Patients must have a negative hepatitis B surface antigen to be enrolled on this study.

  4. Active Hepatitis C

  5. Patients with severe neuropsychiatric lupus or neurologic manifestations of SLE (e.g. stroke, seizure, psychosis, demyelinating syndromes, organic brain syndrome, or lupus related headaches)

  6. Monogenic lupus (known)

  7. Previous autologous or allogenic stem cell transplant

  8. Previous kidney transplant

  9. History of seizure disorder

  10. Patients who are on anti-epileptic therapy

  11. Participation in a clinical trial in which the patient receives an investigational drug within a time period equal or less than 5.5 half-lives of the investigational agent prior to study enrollment.

  12. Subjects who are unwilling or unable to discontinue immunosuppressive medications at the times of CART19 infusion will be excluded from the trial

  13. Any comorbidity that in the opinion of the investigators would jeopardize the ability of the subject to tolerate therapy.

  14. Pregnant patients. All participants of childbearing potential must have negative pregnancy test.

  15. Lactating participants who want to continue breastfeeding.

  16. Patients who are unwilling to consent to LTFU

Studieplan

Denne delen gir detaljer om studieplanen, inkludert hvordan studien er utformet og hva studien måler.

Hvordan er studiet utformet?

Designdetaljer

  • Primært formål: Behandling
  • Tildeling: N/A
  • Intervensjonsmodell: Enkeltgruppeoppdrag
  • Masking: Ingen (Open Label)

Våpen og intervensjoner

Deltakergruppe / Arm
Intervensjon / Behandling
Eksperimentell: CART19

Participants will receive the study product. CART19 cells transduced with a lentiviral vector to express anti-CD19 scFv:41-BB:TCRζ, administered by IV injection.

CART19 cells transduced with a lentiviral vector to express anti-CD19 scFv:41-BB:TCRζ, administered by IV injection.

Hva måler studien?

Primære resultatmål

Resultatmål
Tiltaksbeskrivelse
Tidsramme
Frequency of the dose limiting toxicities of CART19
Tidsramme: up to 24 months post infusion

Frequency of the dose limiting toxicities of CART19

up to 24 months post infusion

Sekundære resultatmål

Resultatmål
Tiltaksbeskrivelse
Tidsramme
2-års total overlevelsesrate
Tidsramme: 24 måneder etter infusjon
24 måneder etter infusjon
2-års bluss gratis overlevelsesrate
Tidsramme: Opptil 24 måneder etter infusjon
Opptil 24 måneder etter infusjon
Rate of childhood SLE Clinical Remission off steroids (cCR-0) within 12 months
Tidsramme: 12 months post treatment
12 months post treatment
Feasibility of manufacturing CART19 for participants with SLE
Tidsramme: up to 24 months post infusion

Feasibility of manufacturing CART19 measured by the percentage of manufactured products that do not meet release criteria for vector transduction efficiency, T cell product purity, viability, or sterility

up to 24 months post infusion
Proportion of patients achieving a complete renal response
Tidsramme: up to 24 months post infusion

renal response will be measured by urine protein/creatinine ratio of < 0.5, normal renal function (serum creatinine ≤ULN) without worsening of baseline serum creatinine by more than 15%, and inactive urinary sediment (<10 red blood cells (RBCs)/high-power field (HPF) without RBC casts)

up to 24 months post infusion
Proportion of patients achieving a partial renal response
Tidsramme: up to 24 months post infusion

partial renal response will be measured by urine protein/creatinine ratio of < 0.5, normal renal function (serum creatinine ≤ULN) without worsening of baseline serum creatinine by more than 15%, and inactive urinary sediment (<10 red blood cells (RBCs)/high-power field (HPF) without RBC casts)

up to 24 months post infusion
Rate of CART19 expansion, persistence or B cell aplasia
Tidsramme: up to 24 months post infusion

Rate of CART19 expansion, persistence and B cell aplasia will be measured by qPCR and flow cytometry

up to 24 months post infusion
Survival of CART19 cells
Tidsramme: up to 24 months post infusion

CART19 cell survival will be measured by utilizing polymerase chain reaction analysis of whole blood to detect and quantify number of cells over time.

up to 24 months post infusion
Elevations in cytokines in serum
Tidsramme: up to 24 months post infusion

to assess bioreactivity and biological response following CART cell infusion, systemic soluble immune and inflammatory factors will be measured by assessing any change in elevations in cytokines in serum prior to infusion and after.

up to 24 months post infusion

Samarbeidspartnere og etterforskere

Det er her du vil finne personer og organisasjoner som er involvert i denne studien.

Etterforskere

  • Hovedetterforsker: Caitlin Elgarten, MD, Children's Hospital of Philadelphia

Studierekorddatoer

Disse datoene sporer fremdriften for innsending av studieposter og sammendragsresultater til ClinicalTrials.gov. Studieposter og rapporterte resultater gjennomgås av National Library of Medicine (NLM) for å sikre at de oppfyller spesifikke kvalitetskontrollstandarder før de legges ut på det offentlige nettstedet.

Studer hoveddatoer

Studiestart (Faktiske)

6. mai 2025

Primær fullføring (Antatt)

28. februar 2030

Studiet fullført (Antatt)

28. februar 2030

Datoer for studieregistrering

Først innsendt

12. februar 2025

Først innsendt som oppfylte QC-kriteriene

17. februar 2025

Først lagt ut (Faktiske)

21. februar 2025

Oppdateringer av studieposter

Sist oppdatering lagt ut (Faktiske)

24. september 2026

Siste oppdatering sendt inn som oppfylte QC-kriteriene

21. september 2026

Sist bekreftet

1. september 2026

Mer informasjon

Begreper knyttet til denne studien

Plan for individuelle deltakerdata (IPD)

Planlegger du å dele individuelle deltakerdata (IPD)?

NEI

Legemiddel- og utstyrsinformasjon, studiedokumenter

Studerer et amerikansk FDA-regulert medikamentprodukt

Ja

Studerer et amerikansk FDA-regulert enhetsprodukt

Nei

Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .

Abonnere